Dexamethasone for cancer-related fatigue in advanced cancer patients - multi-center phase II trial
- Conditions
- A diagnosis of advanced cancer (defined as metastatic or recurrent)Fatigue, Cancer, Dexamethasonenone
- Registration Number
- JPRN-jRCTs031180068
- Lead Sponsor
- Miura Tomofumi
- Brief Summary
The efficacy and safety were evaluated by phase II clinical trial for advanced cancer patients receiving only palliative care and with moderate fatigue. The efficacy and safety were found. However, the efficacy did not achieve the preset outcomes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 32
A diagnosis of advanced cancer (defined as metastatic or recurrent) with fatigue score 4 and more using NRS(0-10)
20 years and older
Prognosis over 30 days
No anti-cancer treatment plan
Inpatient receiving palliative care
Performance status 1-3
Conprehension of Japanese
Provided written informed consent
Patients received corticosteroid therapies within 1 week
Patients received surgery within 4 week
Patients received radiation therapy within 2 week
Patients received anti-tumor treatment within 2 week
Patients had diabetes mellitus, active infection and cognitive disorder
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method